1189126-37-1 Usage
Description
(6-Amino-5-(trifluoromethyl)pyridin-3-yl)boronic acid is a chemical compound characterized by the presence of a boronic acid functional group, a trifluoromethyl group, and a pyridin-3-yl group. It is a white to off-white solid that is widely used in organic synthesis and pharmaceutical research due to its unique properties and reactivity.
Uses
Used in Organic Synthesis:
(6-Amino-5-(trifluoromethyl)pyridin-3-yl)boronic acid is used as a reagent in organic synthesis for the creation of carbon-carbon bonds in organic molecules. Its boronic acid group allows it to participate in Suzuki-Miyaura cross-coupling reactions, a widely used method for forming these bonds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (6-Amino-5-(trifluoromethyl)pyridin-3-yl)boronic acid is used as a building block for the development of new pharmaceuticals. The trifluoromethyl group imparts unique properties to the compound, making it valuable in the design and synthesis of novel drug candidates.
Used in Material Science:
The heteroaromatic character of the pyridin-3-yl group in (6-Amino-5-(trifluoromethyl)pyridin-3-yl)boronic acid increases its usefulness in a variety of chemical reactions, making it a valuable component in the development of new materials with specific properties for various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1189126-37-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,9,1,2 and 6 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1189126-37:
(9*1)+(8*1)+(7*8)+(6*9)+(5*1)+(4*2)+(3*6)+(2*3)+(1*7)=171
171 % 10 = 1
So 1189126-37-1 is a valid CAS Registry Number.
1189126-37-1Relevant articles and documents
SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS
-
, (2012/02/02)
The present invention relates to substituted imidazo[4,5-c]quinoline derivatives, the compounds of formula (I), wherein R1 R2, R3, R4, R5, R6 and R7 are as defined in the specification, processes for their preparation, pharmaceutical compositions comprising compounds of formula (I), and their use in the treatment of diseases or disorders mediated by one or more kinases, particularly proliferative diseases or disorders such as cancer. These compounds can also be used in the treatment of inflammatory diseases and angiogenesis related disorders.
